NFKB1 and cancer: Interestingly, it was shown that in cancer stem cells, a(v)b3 integrin recruits RalB and KRAS to the plasma membrane resulting in the induction of TBK1 and NF‐kB activation which contributes to the refractory status to erlotinib, a tyrosine kinase inhibitor 160.